Pan Cancer T is a biotechnology spin-out from Erasmus MC founded in 2020, Rotterdam, the Netherlands dedicated to discovering and developing T cell receptor (TCR) T cell therapies. The company exploits 20 years of pioneering research in the field of adoptive T cell therapies. This foundation serves as a springboard towards breakthrough therapies for solid tumors.

Pan Cancer T develops natural affinity TCR T cell therapies against unique and proprietary intracellular targets expressed by multiple solid tumors.

Click here to read the impact story of Pan Cancer T.